- Home
- NEOV vs TTRX Comparison
NEOV vs TTRX Comparison
Compare NEOV & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | TTRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.2M | 116.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEOV | TTRX |
|---|---|---|
| Price | $3.22 | $3.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.6M | 31.5K |
| Earning Date | 02-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,060,793.00 | N/A |
| Revenue This Year | $148.14 | N/A |
| Revenue Next Year | $6.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 615.30 | N/A |
| 52 Week Low | $1.80 | $2.57 |
| 52 Week High | $7.13 | $26.50 |
Technical Indicators
Market Signals| Indicator | NEOV | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 31.93 |
| Support Level | $3.76 | $3.55 |
| Resistance Level | $4.78 | $3.80 |
| Average True Range (ATR) | 0.57 | 0.27 |
| MACD | -0.15 | -0.11 |
| Stochastic Oscillator | 5.68 | 2.35 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.